Advertisement

Table of Contents

Breaking Advances

Review

Perspective

Clinical Studies

  • Clinical Studies
    Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma
    Heisoog Kim, Ciprian Catana, Eva-Maria Ratai, Ovidiu C. Andronesi, Dominique L. Jennings, Tracy T. Batchelor, Rakesh K. Jain and A. Gregory Sorensen
    Cancer Res June 1 2011 71 (11) 3745-3752; DOI:10.1158/0008-5472.CAN-10-2991

    Metabolic changes in the tumor and brain tissue during anti-VEGF therapy can serve as imaging biomarkers for predicting treatment response in patients with recurrent malignant glioblastomas.

Integrated Systems and Technologies

  • Integrated Systems and Technologies
    Preclinical Validation of Electrochemotherapy as an Effective Treatment for Brain Tumors
    Birgit Agerholm-Larsen, Helle K. Iversen, Per Ibsen, Jakob M. Moller, Faisal Mahmood, Kurt Svarre Jensen and Julie Gehl
    Cancer Res June 1 2011 71 (11) 3753-3762; DOI:10.1158/0008-5472.CAN-11-0451

    Enhancing drug uptake through the use of a novel electrode technology can achieve high rates of complete response in a rat model of brain cancer.

Microenvironment and Immunology

Molecular and Cellular Pathobiology

  • Molecular and Cellular Pathobiology
    CD24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization
    Jonathan B. Overdevest, Shibu Thomas, Glen Kristiansen, Donna E. Hansel, Steven C. Smith and Dan Theodorescu
    Cancer Res June 1 2011 71 (11) 3802-3811; DOI:10.1158/0008-5472.CAN-11-0519

    Findings offer preclinical proof-of-concept for antibody targeting of a marker of metastatic progression as a potential new adjuvant therapy for clinical investigation.

  • Molecular and Cellular Pathobiology
    An EGFR-ERK-SOX9 Signaling Cascade Links Urothelial Development and Regeneration to Cancer
    Shizhang Ling, Xiaofei Chang, Luciana Schultz, Thomas K. Lee, Alcides Chaux, Luigi Marchionni, George J. Netto, David Sidransky and David M. Berman
    Cancer Res June 1 2011 71 (11) 3812-3821; DOI:10.1158/0008-5472.CAN-10-3072

    Cells undergoing injury turn on EGF ligand production, which induces the developmental transcription factor SOX9 and supports emergence of a migratory, invasive phenotype.

  • Molecular and Cellular Pathobiology
    Epithelial Cell Organization Suppresses Myc Function by Attenuating Myc Expression
    David R. Simpson, Min Yu, Siyuan Zheng, Zhongming Zhao, Senthil K. Muthuswamy and William P. Tansey
    Cancer Res June 1 2011 71 (11) 3822-3830; DOI:10.1158/0008-5472.CAN-10-3782

    This study finds that epithelial cell organization does not pose a barrier to Myc oncogenicity, pointing to roles for tumor suppression mechanisms other than three-dimensional structure in antagonizing Myc during carcinogenesis.

  • Molecular and Cellular Pathobiology
    Bone Marrow Stroma–Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor
    Taghi Manshouri, Zeev Estrov, Alfonso Quintás-Cardama, Jan Burger, Ying Zhang, Ana Livun, Liza Knez, David Harris, Chad J. Creighton, Hagop M. Kantarjian and Srdan Verstovsek
    Cancer Res June 1 2011 71 (11) 3831-3840; DOI:10.1158/0008-5472.CAN-10-4002

    Myeloproliferative neoplasms rely on support from stromal cells in the bone marrow microenvironment that release IL-6, FGF, and CXCL10.

  • Molecular and Cellular Pathobiology
    A Genome-Wide Search for Promoters That Respond to Increased MYCN Reveals Both New Oncogenic and Tumor Suppressor MicroRNAs Associated with Aggressive Neuroblastoma
    Jason M. Shohet, Rajib Ghosh, Cristian Coarfa, Andrew Ludwig, Ashley L. Benham, Zaowen Chen, Danielle M. Patterson, Eveline Barbieri, Pieter Mestdagh, Denae N. Sikorski, Aleksandar Milosavljevic, Eugene S. Kim and Preethi H. Gunaratne
    Cancer Res June 1 2011 71 (11) 3841-3851; DOI:10.1158/0008-5472.CAN-10-4391

    N-Myc activation is associated with direct repression of a microRNA program that is not generally suppressive to neuroblastoma cells, with possible implications for how to better attack this aggressive pediatric cancer.

  • Molecular and Cellular Pathobiology
    The Melanoma‐Upregulated Long Noncoding RNA SPRY4-IT1 Modulates Apoptosis and Invasion
    Divya Khaitan, Marcel E. Dinger, Joseph Mazar, Joanna Crawford, Martin A. Smith, John S. Mattick and Ranjan J. Perera
    Cancer Res June 1 2011 71 (11) 3852-3862; DOI:10.1158/0008-5472.CAN-10-4460

    Long noncoding RNAs (lncRNAs) are a rapidly emerging area of cancer research because of their suspected roles in interacting with messenger RNAs, regulatory microRNAs, and proteins and modulating their functions.

  • Molecular and Cellular Pathobiology
    Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse
    Roch-Philippe Charles, Gioia Iezza, Elena Amendola, David Dankort and Martin McMahon
    Cancer Res June 1 2011 71 (11) 3863-3871; DOI:10.1158/0008-5472.CAN-10-4463

    Studies of thyroid cancer, the most common endocrine cancer, will benefit from the development of a high-penetrance, genetically- engineered mouse model, which recapitulates key features of the genetics and pathophysiology of the human disease.

  • Molecular and Cellular Pathobiology
    Mild Elevation of Body Temperature Reduces Tumor Interstitial Fluid Pressure and Hypoxia and Enhances Efficacy of Radiotherapy in Murine Tumor Models
    Arindam Sen, Maegan L. Capitano, Joseph A. Spernyak, John T. Schueckler, Seneca Thomas, Anurag K. Singh, Sharon S. Evans, Bonnie L. Hylander and Elizabeth A. Repasky
    Cancer Res June 1 2011 71 (11) 3872-3880; DOI:10.1158/0008-5472.CAN-10-4482

    Preclinical findings show how mild systemic hyperthermia in mice bearing tumors can increase tumor blood flow and improve the efficacy radiation therapy, prompting immediate attention for clinical evaluation.

Prevention and Epidemiology

  • Prevention and Epidemiology
    A Multistage Association Study Identifies a Breast Cancer Genetic Locus at NCOA7
    Kathryn S.P. Higginbotham, Joan P. Breyer, Kevin M. Bradley, Peggy A. Schuyler, W. Dale Plummer Jr., Marcia E. Freudenthal, Amy Trentham-Dietz, Polly A. Newcomb, Melinda E. Sanders, David L. Page, Fritz F. Parl, Kathleen M. Egan, William D. Dupont and Jeffrey R. Smith
    Cancer Res June 1 2011 71 (11) 3881-3888; DOI:10.1158/0008-5472.CAN-10-2653

    A large genetic association study of growth factor signaling and estrogen metabolism defines a variant in an estrogen receptor-binding transcriptional co-activator that may confer a reduced risk of breast cancer.

  • Prevention and Epidemiology
    LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer
    Jennifer Permuth-Wey, Donghwa Kim, Ya-Yu Tsai, Hui-Yi Lin, Y. Ann Chen, Jill Barnholtz-Sloan, Michael J. Birrer, Gregory Bloom, Stephen J. Chanock, Zhihua Chen, Daniel W. Cramer, Julie M. Cunningham, Getachew Dagne, Judith Ebbert-Syfrett, David Fenstermacher, Brooke L. Fridley, Montserrat Garcia-Closas, Simon A. Gayther, William Ge, Aleksandra Gentry-Maharaj, Jesus Gonzalez-Bosquet, Ellen L. Goode, Edwin Iversen, Heather Jim, William Kong, John McLaughlin, Usha Menon, Alvaro N.A. Monteiro, Steven A. Narod, Paul D.P. Pharoah, Catherine M. Phelan, Xiaotao Qu, Susan J. Ramus, Harvey Risch, Joellen M. Schildkraut, Honglin Song, Heather Stockwell, Rebecca Sutphen, Kathryn L. Terry, Jonathan Tyrer, Robert A. Vierkant, Nicolas Wentzensen, Johnathan M. Lancaster, Jin Q. Cheng and Thomas A. Sellers
    Cancer Res June 1 2011 71 (11) 3896-3903; DOI:10.1158/0008-5472.CAN-10-4167

    Common inherited variants in miRNA biogenesis genes may be useful to identify high-risk populations and to develop novel cancer diagnostic, prognostic, and therapeutic strategies.

  • Prevention and Epidemiology
    Identification of an Unintended Consequence of Nrf2-Directed Cytoprotection against a Key Tobacco Carcinogen plus a Counteracting Chemopreventive Intervention
    Joseph D. Paonessa, Yi Ding, Kristen L. Randall, Rex Munday, Dayana Argoti, Paul Vouros and Yuesheng Zhang
    Cancer Res June 1 2011 71 (11) 3904-3911; DOI:10.1158/0008-5472.CAN-11-0396

    An important cytoprotective factor is found to sensitize the bladder to a major tobacco carcinogen, but a chemopreventive strategy is suggested to limit this pitfall.

Therapeutics, Targets, and Chemical Biology

  • Therapeutics, Targets, and Chemical Biology
    Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
    Leo Kretzner, Anna Scuto, Pamela M. Dino, Claudia M. Kowolik, Jun Wu, Patrick Ventura, Richard Jove, Stephen J. Forman, Yun Yen and Mark H. Kirschbaum
    Cancer Res June 1 2011 71 (11) 3912-3920; DOI:10.1158/0008-5472.CAN-10-2259

    Proof-of-concept and mechanistic findings prompt clinical evaluation for a novel drug combination that could improve cancer treatment.

  • Therapeutics, Targets, and Chemical Biology
    Erlotinib-Mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4
    Kevin P. Orcutt, Arlene D. Parsons, Zita A. Sibenaller, Peter M. Scarbrough, Yueming Zhu, Arya Sobhakumari, Werner W. Wilke, Amanda L. Kalen, Prabhat Goswami, Francis J. Miller Jr., Douglas R. Spitz and Andrean L. Simons
    Cancer Res June 1 2011 71 (11) 3932-3940; DOI:10.1158/0008-5472.CAN-10-3425

    Findings suggest that the cytotoxicity of EGFR kinase inhibitors in cancer cells may be based in large part on induction of oxidative stress via hydrogen peroxide produced by NOX4 signaling.

  • Therapeutics, Targets, and Chemical Biology
    ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis
    Rebecca S. Cook, Joan T. Garrett, Violeta Sánchez, Jamie C. Stanford, Christian Young, Anindita Chakrabarty, Cammie Rinehart, Yixian Zhang, Yaming Wu, Lee Greenberger, Ivan D. Horak and Carlos L. Arteaga
    Cancer Res June 1 2011 71 (11) 3941-3951; DOI:10.1158/0008-5472.CAN-10-3775

    Findings offer preclinical proof-of-concept that ErbB3 disruption may be therapeutically effective in PI3K/Akt-driven breast cancers.

  • Therapeutics, Targets, and Chemical Biology
    Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
    Krystyna M. Wozniak, Kenichi Nomoto, Rena G. Lapidus, Ying Wu, Valentina Carozzi, Guido Cavaletti, Kazuhiro Hayakawa, Satoru Hosokawa, Murray J. Towle, Bruce A. Littlefield and Barbara S. Slusher
    Cancer Res June 1 2011 71 (11) 3952-3962; DOI:10.1158/0008-5472.CAN-10-4184

    Compared to taxanes and epothilones, the two major classes of antimitotic drugs used in cancer treatment, a new FDA approved antitubulin drug may cause far less debilitating nerve damage in cancer survivors.

  • Therapeutics, Targets, and Chemical Biology
    Convection-Enhanced Delivery of Topotecan into a PDGF-Driven Model of Glioblastoma Prolongs Survival and Ablates Both Tumor-Initiating Cells and Recruited Glial Progenitors
    Kim A. Lopez, Aaron M. Tannenbaum, Marcela C. Assanah, Katy Linskey, Jonathan Yun, Alayar Kangarlu, Orlando D. Gil, Peter Canoll and Jeffrey N. Bruce
    Cancer Res June 1 2011 71 (11) 3963-3971; DOI:10.1158/0008-5472.CAN-10-0906

    The findings of this study suggest that chemotherapy may prime later recurrence by decreasing recruitment of normal glial progenitor cells into a brain tumor microenvironment.

  • Therapeutics, Targets, and Chemical Biology
    6-Bromoindirubin-3′-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells
    Lucy Liu, Sangkil Nam, Yan Tian, Fan Yang, Jun Wu, Yan Wang, Anna Scuto, Panos Polychronopoulos, Prokopios Magiatis, Leandros Skaltsounis and Richard Jove
    Cancer Res June 1 2011 71 (11) 3972-3979; DOI:10.1158/0008-5472.CAN-10-3852

    Inhibitors of the JAK/STAT3 signaling pathway represent a very appealing therapeutic direction because of the central importance of this pathway in tumor cells and the tumor microenvironment in sustaining malignant growth and progression.

Tumor and Stem Cell Biology

Corrections

Back to top
Cancer Research: 71 (11)
June 2011
Volume 71, Issue 11

Sign up for alerts

Issue Highlights

Jump to

Advertisement